Fintel · Aug 4, 2026
GK
NYSE · GKOS
Glaukos Corporation
Healthcare · Medical - Devices
$184.89
Up+$0.00 (+0.00%)
Updated Aug 23, 2026, 12:37 AM
SID Score
6.3/10
Composite research score
Smart Money
56/100
Neutral
- Market cap
- 6.27B
- P/E ratio
- -71.17
- Dividend yield
- 0.00%
- 52-week range
- $95.87 – $191.62
- Volume
- 440.1K
- Avg. volume
- 1.14M
Price performance
GKOS price history
1M range · 20 trading sessions · Daily adjusted prices
GKOS closed at $184.89 after 20 trading sessions, up 21.71% for the selected period.
- Last close
- $184.89
- Period change
- +21.71%
- Period low
- $151.33
- Period high
- $189.55
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $185.00 | $187.60 | $183.68 | $184.89 | 440.1K |
| Aug 20, 2026 | $187.73 | $191.62 | $183.245 | $184.89 | 791.87K |
| Aug 19, 2026 | $186.00 | $190.06 | $185.96 | $189.55 | 505.43K |
| Aug 18, 2026 | $185.00 | $186.66 | $175.04 | $184.15 | 625.63K |
| Aug 17, 2026 | $183.55 | $186.03 | $181.84 | $185.62 | 734.77K |
| Aug 14, 2026 | $189.89 | $190.00 | $184.22 | $184.53 | 743.41K |
| Aug 13, 2026 | $187.00 | $189.69 | $185.82 | $189.45 | 762.15K |
| Aug 12, 2026 | $179.80 | $186.75 | $177.565 | $186.63 | 754.15K |
| Aug 11, 2026 | $180.47 | $183.91 | $178.58 | $182.00 | 723.32K |
| Aug 10, 2026 | $180.00 | $183.49 | $178.78 | $181.42 | 646.07K |
| Aug 7, 2026 | $172.94 | $180.62 | $172.215 | $180.02 | 768.79K |
| Aug 6, 2026 | $171.17 | $171.99 | $168.39 | $170.99 | 575K |
| Aug 5, 2026 | $172.01 | $172.01 | $167.81 | $170.93 | 705.74K |
| Aug 4, 2026 | $171.75 | $172.91 | $167.64 | $170.53 | 799.74K |
| Aug 3, 2026 | $168.66 | $173.9799 | $168.60 | $170.87 | 1.11M |
| Jul 31, 2026 | $166.58 | $171.545 | $165.37 | $166.72 | 1.03M |
| Jul 30, 2026 | $180.22 | $184.00 | $165.775 | $168.52 | 2.56M |
| Jul 29, 2026 | $149.71 | $166.00 | $145.7759 | $161.66 | 3.14M |
| Jul 28, 2026 | $153.62 | $154.98 | $146.03 | $151.33 | 1.14M |
| Jul 27, 2026 | $155.54 | $156.15 | $148.02 | $151.91 | 727.53K |
Latest GKOS news
The latest Smart Investors Daily articles mentioning GKOS.
Stock researchCompany · Overview
GKOS research
Overview
Company profile and research snapshot.
Company profile
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $121.38
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 20, 2026 | BTIG | Buy | — |
| Jul 30, 2026 | Needham | Buy | — |
| Jul 30, 2026 | Wells Fargo | Overweight | — |
| Jul 30, 2026 | BTIG | Buy | — |
| Jul 30, 2026 | Stifel | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Jul 30, 2026
UBS Maintains Neutral on Glaukos, Raises Price Target to $172
UBS analyst Patrick Wood maintains Glaukos (NYSE:GKOS) with a Neutral and raises the price target from $150 to $172.
Benzinga · Jul 30, 2026
HC Wainwright & Co. Maintains Buy on Glaukos, Raises Price Target to $195
HC Wainwright & Co. analyst Yi Chen maintains Glaukos (NYSE:GKOS) with a Buy and raises the price target from $168 to $195.
Benzinga · Jul 30, 2026
Citigroup Maintains Buy on Glaukos, Raises Price Target to $188
Citigroup analyst Joanne Wuensch maintains Glaukos (NYSE:GKOS) with a Buy and raises the price target from $175 to $188.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
